Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SDGR
stocks logo

SDGR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
83.22M
-5.78%
-0.183
-66.75%
72.55M
+21.83%
-0.490
-40.24%
64.21M
+17.25%
-0.623
+5.65%
Estimates Revision
The market is revising Downward the revenue expectations for Schrödinger, Inc. (SDGR) for FY2025, with the revenue forecasts being adjusted by -0.03% over the past three months. During the same period, the stock price has changed by -3.71%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.03%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-12.78%
In Past 3 Month
Stock Price
Go Down
down Image
-3.71%
In Past 3 Month
Wall Street analysts forecast SDGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SDGR is 26.50 USD with a low forecast of 21.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast SDGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SDGR is 26.50 USD with a low forecast of 21.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 18.420
sliders
Low
21.00
Averages
26.50
High
33.00
Current: 18.420
sliders
Low
21.00
Averages
26.50
High
33.00
Goldman Sachs
Neutral
initiated
$19
2025-09-29
Reason
Goldman Sachs
Price Target
$19
2025-09-29
initiated
Neutral
Reason
Goldman Sachs initiated coverage of Schrodinger with a Neutral rating and $19 price target. The company's software business serves as the core revenue driver, but visibility on the forward growth profile is limited, and the firm is looking for clarity on efforts to deepen customer utilization and grow the number of customers with larger annual contract value via expanded and differentiated technology/platform offerings, the analyst tells investors in a research note. Goldman adds that it is also monitoring progress with the proprietary drug discovery pipeline, noting recent Phase 1 SGR-1505 data in hematologic malignancies, together with upcoming initial Phase 1 SGR-3515 data in solid tumors, if positive, could further validate Schrodinger's platform.
Citi
Buy -> Neutral
downgrade
$35 -> $20
2025-08-14
Reason
Citi
Price Target
$35 -> $20
2025-08-14
downgrade
Buy -> Neutral
Reason
Citi downgraded Schrodinger to Neutral from Buy with a price target of $20, down from $35. The firm cites the recent developments in the company's internally developed drug pipeline as well as continued headwinds facing the biotech and pharma industries, the analyst tells investors in a research note. Citi adds that its positive stance was largely based on the three shots on goal the company had in its early stage Phase 1 assets to highlight how its drug development platform could discover novel targets that biopharma partners would be interested in, but to date, Schrodinger's recent updates have fallen short, raising concerns on the potential of the company's proprietary drug portfolio efforts.
Barclays
Overweight
initiated
$25
2025-08-14
Reason
Barclays
Price Target
$25
2025-08-14
initiated
Overweight
Reason
Barclays initiated coverage of Schrodinger with an Overweight rating and $25 price target. The firm sees two "value-inflecting" data readouts for the company Q4. Schrodinger will announce initial Phase 1 data for SGR- 2921 and for SGR-3515 in advanced solid tumors, the analyst tells investors in a research note.
Morgan Stanley
Sean Laaman
Equal Weight
downgrade
$31 -> $28
2025-07-03
Reason
Morgan Stanley
Sean Laaman
Price Target
$31 -> $28
2025-07-03
downgrade
Equal Weight
Reason
Morgan Stanley analyst Sean Laaman assumed coverage of Schrodinger with an Equal Weight rating with a price target of $28, down from $31. Schrodinger has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. Schrodinger's software business provides a steady stream of revenue that acts as a safety net for the stock, regardless of the outcomes of partnerships and the proprietary pipeline, the firm says.
Keybanc
Scott Schoenhaus
Buy
Maintains
$30 → $32
2025-04-16
Reason
Keybanc
Scott Schoenhaus
Price Target
$30 → $32
2025-04-16
Maintains
Buy
Reason
KeyBanc analyst Scott Schoenhaus raised the firm's price target on Schrodinger to $32 from $30 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.
Piper Sandler
Joseph Catanzaro
Buy
Maintains
$50 → $45
2025-02-27
Reason
Piper Sandler
Joseph Catanzaro
Price Target
$50 → $45
2025-02-27
Maintains
Buy
Reason
Piper Sandler lowered the firm's price target on Schrodinger to $45 from $50 and keeps an Overweight rating on the shares following quarterly results. The firm notes Schrodinger reiterated that it expects to report initial clinical data from 3 programs in 2025. Specifically, it refined guidance for SGR-1505, now expecting to report data in Q2 2025.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Schrodinger Inc (SDGR.O) is -9.46, compared to its 5-year average forward P/E of -24.83. For a more detailed relative valuation and DCF analysis to assess Schrodinger Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-24.83
Current PE
-9.46
Overvalued PE
49.91
Undervalued PE
-99.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-16.98
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.30
Undervalued EV/EBITDA
-38.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
13.86
Current PS
0.00
Overvalued PS
25.51
Undervalued PS
2.21
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SDGR News & Events

Events Timeline

(ET)
2025-12-02
10:50:00
FDA Proposes Guidance for Streamlined Safety Assessments of Monospecific Antibodies
select
link
2025-11-05 (ET)
2025-11-05
16:12:55
Schrodinger announces Q3 adjusted EPS of 51 cents, falling short of consensus estimate of 74 cents.
select
2025-11-05
16:12:39
Schrodinger anticipates 8%-13% growth in software revenue for FY25
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
11-11NASDAQ.COM
Analysts Predict HAPS Will Hit $37

  • ETF Analysis: The Harbor Human Capital Factor US Small Cap ETF (HAPS) has an implied analyst target price of $37.46, indicating a potential upside of 20.68% from its current trading price of $31.04.

  • Notable Holdings: Key underlying holdings of HAPS, such as Schrodinger Inc (SDGR), Stratasys, Ltd. (SSYS), and Encore Capital Group Inc (ECPG), show significant upside potential based on analyst target prices, with SDGR at 43.14% higher, SSYS at 38.89%, and ECPG at 21.47%.

  • Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to future downgrades if they do not align with recent developments.

  • Investor Research: Investors are encouraged to conduct further research to assess the validity of analyst targets and their alignment with current market conditions and company performance.

[object Object]
Preview
7.0
11-06SeekingAlpha
Schrödinger Revises 2025 Software Growth Forecast to 8%-13% Due to Pharma Scale-Up Delays and Emphasis on Operational Efficiency

  • Management Overview: CEO Ramy Farid reported a 54% increase in total revenue to $54 million for Q3 2025, driven by strong demand for software and drug discovery solutions, while adjusting software revenue growth guidance to 8%-13% due to delays in pharma scale-up opportunities.

  • Financial Performance: The company achieved software revenue of $40.9 million and drug discovery revenue of $13.5 million, with a net loss of $33 million. Operating expenses decreased, and cash reserves stood at $401 million as of September 30.

  • Strategic Focus: Schrödinger is shifting its strategy away from advancing internal discovery programs independently, emphasizing early-stage discovery partnerships and operational efficiency to navigate current market challenges.

  • Analyst Sentiment: Analysts expressed concerns about customer acquisition and growth visibility, noting a cautious tone from management regarding near-term uncertainties, while maintaining optimism about long-term growth potential.

[object Object]
Preview
3.0
10-26Yahoo Finance
Will Schrödinger (SDGR) Maintain Its AI Advantage in Drug Discovery Ahead of Q3 Results?

  • Upcoming Financial Results: Schrödinger will announce its Q3 2025 financial results on November 5, 2025, followed by a live investor call, although this event is not expected to significantly impact the company's near-term catalysts or risks.

  • AI Leadership and Drug Discovery: The company is gaining recognition for its AI-driven software aimed at enhancing drug discovery, which is crucial for attracting investment and achieving scalable revenues, despite challenges in client acquisition.

  • Clinical Progress and Revenue Projections: Schrödinger's SGR-1505, a MALT1 inhibitor, has shown early efficacy and received FDA Fast Track designation, positioning it as a key driver for future revenue growth, with projections of $396.6 million in revenue by 2028.

  • Valuation Insights: Current fair value estimates for Schrödinger's stock range from $27.00 to $43.20 per share, indicating potential upside, but concerns about slow client acquisition may affect long-term growth and market sentiment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Schrodinger Inc (SDGR) stock price today?

The current price of SDGR is 18.42 USD — it has increased 3.83 % in the last trading day.

arrow icon

What is Schrodinger Inc (SDGR)'s business?

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.

arrow icon

What is the price predicton of SDGR Stock?

Wall Street analysts forecast SDGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SDGR is 26.50 USD with a low forecast of 21.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Schrodinger Inc (SDGR)'s revenue for the last quarter?

Schrodinger Inc revenue for the last quarter amounts to 54.32M USD, increased 53.94 % YoY.

arrow icon

What is Schrodinger Inc (SDGR)'s earnings per share (EPS) for the last quarter?

Schrodinger Inc. EPS for the last quarter amounts to -0.45 USD, decreased -13.46 % YoY.

arrow icon

What changes have occurred in the market's expectations for Schrodinger Inc (SDGR)'s fundamentals?

The market is revising Downward the revenue expectations for Schrödinger, Inc. (SDGR) for FY2025, with the revenue forecasts being adjusted by -0.03% over the past three months. During the same period, the stock price has changed by -3.71%.
arrow icon

How many employees does Schrodinger Inc (SDGR). have?

Schrodinger Inc (SDGR) has 891 emplpoyees as of December 05 2025.

arrow icon

What is Schrodinger Inc (SDGR) market cap?

Today SDGR has the market capitalization of 1.36B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free